Rapport Therapeutics (RAPP) is back in focus after new efficacy data for its lead candidate RAP-219, progress toward Phase 3 planning, and weaker trial results from a competing epilepsy therapy.

Despite the latest data and analyst attention, Rapport Therapeutics’ share price has slipped 8.6% over the past week and 5.1% over the past month. However, its 90 day share price return of 18.2% and one year total shareholder return of about 2x suggest momentum has been building over a longer window.

If RAP-219’s progress has you rethinking where growth in healthcare could come from next, it may be worth widening your search with a focused list of 39 healthcare AI stocks.

With shares down over the past month but up sharply over the past year, and the stock trading below several analyst targets, the key question is whether Rapport is still undervalued or if the market is already pricing in future growth.

Preferred Price to Book Ratio of 3.7x: Is it justified?

On a P/B basis, Rapport Therapeutics currently looks expensive compared to peers, which is an important context for anyone reassessing the recent share price pullback.

The P/B ratio compares the company’s market value to its book value, or net assets. It is often used for early stage or unprofitable biopharma stocks where earnings are not yet a reliable guide. With Rapport still unprofitable and forecast to remain so over the next 3 years, investors appear to be paying a premium for its pipeline and growth expectations rather than its current financials.

Compared with both its direct peers and the broader US pharmaceuticals industry, that premium is clear. Rapport’s P/B of 3.7x is higher than the peer average of 3.2x and stands well above the wider US Pharmaceuticals industry average of 2.2x, suggesting the stock is priced more richly than many alternatives in the sector.

Result: Price-to-book of 3.7x (OVERVALUED)

However, investors also face real risks if clinical timelines slip or future RAP-219 data fail to support the premium P/B and the current long term share gains.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Mixed signals on value and risk so far? If you want to move quickly and form your own view from the data, start with the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If you stop with just one stock, you risk missing out on other opportunities that fit your style, time horizon, and comfort with risk.

• Target potential mispricings by scanning a curated set of 49 high quality undervalued stocks that pair stronger fundamentals with more attractive entry points.
• Strengthen the foundation of your portfolio by focusing on companies in the solid balance sheet and fundamentals stocks screener (46 results) that can better handle shocks and surprises.
• Get ahead of the crowd by reviewing a screener containing 21 high quality undiscovered gems before they sit on everyone else’s watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.